Literature DB >> 19893332

Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users.

A C Parrott1.   

Abstract

AIMS: 3,4-Methylenedioxymethamphetamine (MDMA) can affect both neurotransmitter and neurohormonal activity. This review will debate the role of the metabolic activation hormone cortisol for the psychobiological effects of ecstasy/MDMA.
METHODS: The empirical literature on cortisol release following acute MDMA administration and cortisol functioning in drug-free recreational ecstasy/MDMA users will be reviewed. This will be followed by an overview of cortisol as a bioenergetic stress neurohormone, and a debate on how it could be modulating the acute and chronic psychobiological effects of MDMA.
RESULTS: Cortisol release is increased by stimulatory factors, including physical activity, thermal stress and stimulant drugs. In laboratory studies MDMA leads to an acute cortisol increase of around 150% in sedentary humans. In MDMA-using dance clubbers, the cortisol levels are increased by around 800%, possibly due to the combined factors of stimulant drug, physical exertion and psychosocial stimulation. Regular ecstasy/MDMA users also demonstrate changes in baseline cortisol levels and cortisol reactivity, with compromised hypothalamic-pituitary-adrenal activity. Nonpharmacological research has shown how cortisol is important for psychological aspects such as memory, cognition, sleep, impulsivity, depression and neuronal damage. These same functions are often impaired in recreational ecstasy/MDMA users, and cortisol may be an important modulatory co-factor.
CONCLUSIONS: The energizing hormone cortisol is involved in the psychobiology of MDMA, probably via its effects on energy metabolism. Acute cortisol release may potentiate the stimulating effects of MDMA in dance clubbers. Chronically, cortisol may contribute to the variance in functional and structural consequences of repeated ecstasy usage. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893332      PMCID: PMC2826870          DOI: 10.1159/000253551

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  111 in total

Review 1.  Sleep deprivation as a neurobiologic and physiologic stressor: Allostasis and allostatic load.

Authors:  Bruce S McEwen
Journal:  Metabolism       Date:  2006-10       Impact factor: 8.694

2.  Impaired declarative memory consolidation during sleep in patients with primary insomnia: Influence of sleep architecture and nocturnal cortisol release.

Authors:  Jutta Backhaus; Klaus Junghanns; Jan Born; Kornelia Hohaus; Frauke Faasch; Fritz Hohagen
Journal:  Biol Psychiatry       Date:  2006-07-28       Impact factor: 13.382

3.  Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users.

Authors:  A C Parrott; E Sisk; J J Turner
Journal:  Drug Alcohol Depend       Date:  2000-07-01       Impact factor: 4.492

4.  Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.

Authors:  A C Parrott; T Buchanan; A B Scholey; T Heffernan; J Ling; J Rodgers
Journal:  Hum Psychopharmacol       Date:  2002-08       Impact factor: 1.672

5.  MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.

Authors:  J L Reay; C Hamilton; D O Kennedy; A B Scholey
Journal:  J Psychopharmacol       Date:  2006-05       Impact factor: 4.153

6.  Serum cortisol response to incremental work in experienced and naive subjects.

Authors:  H A Davis; G C Gass; J R Bassett
Journal:  Psychosom Med       Date:  1981-04       Impact factor: 4.312

7.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

8.  Psychosocial stress impairs working memory at high loads: an association with cortisol levels and memory retrieval.

Authors:  N Y L Oei; W T A M Everaerd; B M Elzinga; S van Well; B Bermond
Journal:  Stress       Date:  2006-09       Impact factor: 3.493

Review 9.  Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

10.  Persistent neuropsychological problems after 7 years of abstinence from recreational Ecstasy (MDMA): a case study.

Authors:  K Soar; A C Parrott; H C Fox
Journal:  Psychol Rep       Date:  2004-08
View more
  15 in total

1.  Ecstacy-associated hyponatremia: why are women at risk?

Authors:  Michael L Moritz; Kamyar Kalantar-Zadeh; Juan Carlos Ayus
Journal:  Nephrol Dial Transplant       Date:  2013-06-26       Impact factor: 5.992

2.  Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.

Authors:  Mark A Wetherell; Catharine Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2013-11-05       Impact factor: 4.530

3.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

4.  MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study.

Authors:  Andrew C Parrott; Amy Gibbs; Andrew B Scholey; Rebecca King; Katherine Owens; Phil Swann; Ed Ogden; Con Stough
Journal:  Psychopharmacology (Berl)       Date:  2011-02-12       Impact factor: 4.530

5.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

6.  MDMA does not alter responses to the Trier Social Stress Test in humans.

Authors:  Anya K Bershad; Melissa A Miller; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2017-04-21       Impact factor: 4.530

7.  Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Hum Psychopharmacol       Date:  2015-07       Impact factor: 1.672

8.  Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users.

Authors:  Oliver G Bosch; Michael Wagner; Frank Jessen; Kai-Uwe Kühn; Alexius Joe; Erich Seifritz; Wolfgang Maier; Hans-Jürgen Biersack; Boris B Quednow
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

9.  Meta-analysis of executive functioning in ecstasy/polydrug users.

Authors:  C A Roberts; A Jones; C Montgomery
Journal:  Psychol Med       Date:  2016-03-11       Impact factor: 7.723

10.  Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory.

Authors:  K P C Kuypers; R de la Torre; M Farre; M Pujadas; J G Ramaekers
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.